HealthInvest Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

HealthInvest Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$42.8K	Buy	+414	New	+$38.9K	0.08%	23

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HealthInvest Partners's BMRN Position: Q4 2022 in Review

HealthInvest Partners opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2022: 414 shares worth $42.8K. The stake represents 0.08% of the portfolio and ranks #23 among its holdings.

581 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

HealthInvest Partners held 414 shares of BioMarin Pharmaceuticals worth $42.8K as of Q4 2022.
BioMarin Pharmaceuticals was a new HealthInvest Partners position in Q4 2022.
BioMarin Pharmaceuticals made up 0.08% of HealthInvest Partners's portfolio in Q4 2022, its #23 holding.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.